1102 related articles for article (PubMed ID: 29626326)
21. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
[TBL] [Abstract][Full Text] [Related]
22. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
Poulin P; Theil FP
J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
[TBL] [Abstract][Full Text] [Related]
23. Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics.
Zou P; Zheng N; Yu Y; Yu S; Sun W; McEachem D; Yang Y; Yu LX; Wang S; Sun D
J Pharm Pharm Sci; 2012; 15(2):265-80. PubMed ID: 22579006
[TBL] [Abstract][Full Text] [Related]
24. Predicting the effect of cytochrome P450 inhibitors on substrate drugs: analysis of physiologically based pharmacokinetic modeling submissions to the US Food and Drug Administration.
Wagner C; Pan Y; Hsu V; Grillo JA; Zhang L; Reynolds KS; Sinha V; Zhao P
Clin Pharmacokinet; 2015 Jan; 54(1):117-27. PubMed ID: 25260695
[TBL] [Abstract][Full Text] [Related]
25. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
[TBL] [Abstract][Full Text] [Related]
26. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
Arora S; Pansari A; Kilford PJ; Jamei M; Turner DB; Gardner I
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):483-495. PubMed ID: 35486324
[TBL] [Abstract][Full Text] [Related]
27. Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.
Xu R; Ge W; Jiang Q
Eur J Clin Pharmacol; 2018 Jun; 74(6):755-765. PubMed ID: 29453492
[TBL] [Abstract][Full Text] [Related]
28. Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man.
Allan G; Davis J; Dickins M; Gardner I; Jenkins T; Jones H; Webster R; Westgate H
Xenobiotica; 2008 Jun; 38(6):620-40. PubMed ID: 18570162
[TBL] [Abstract][Full Text] [Related]
29. The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model.
Musther H; Harwood MD; Yang J; Turner DB; Rostami-Hodjegan A; Jamei M
J Pharm Sci; 2017 Sep; 106(9):2826-2838. PubMed ID: 28495566
[TBL] [Abstract][Full Text] [Related]
30. Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib.
Lin L; Wright MR; Hop CECA; Wong H
Drug Metab Dispos; 2022 Sep; 50(9):1170-1181. PubMed ID: 35779865
[TBL] [Abstract][Full Text] [Related]
31. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans.
Luttringer O; Theil FP; Poulin P; Schmitt-Hoffmann AH; Guentert TW; Lavé T
J Pharm Sci; 2003 Oct; 92(10):1990-2007. PubMed ID: 14502539
[TBL] [Abstract][Full Text] [Related]
32. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
[TBL] [Abstract][Full Text] [Related]
33. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.
Min JS; Kim D; Park JB; Heo H; Bae SH; Seo JH; Oh E; Bae SK
Drug Des Devel Ther; 2016; 10():2959-2972. PubMed ID: 27695293
[TBL] [Abstract][Full Text] [Related]
34. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
35. Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization.
Zhang Y; Zhao S; Wang C; Zhou P; Zhai S
Front Pharmacol; 2021; 12():636097. PubMed ID: 33815119
[No Abstract] [Full Text] [Related]
36. Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach.
Iwasaki S; Kosugi Y; Zhu AZX; Nakagawa S; Sano N; Funami M; Kosaka M; Furuta A; Hirabayashi H; Amano N
Xenobiotica; 2019 Nov; 49(11):1251-1259. PubMed ID: 30516093
[TBL] [Abstract][Full Text] [Related]
37. A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions.
Conner TM; Reed RC; Zhang T
Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):389-408. PubMed ID: 30460522
[TBL] [Abstract][Full Text] [Related]
38. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
[TBL] [Abstract][Full Text] [Related]
39. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
Nakamaru Y; Emoto C; Shimizu M; Yamazaki H
Biopharm Drug Dispos; 2015 Apr; 36(3):148-62. PubMed ID: 25450725
[TBL] [Abstract][Full Text] [Related]
40. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
Yu Y; Loi CM; Hoffman J; Wang D
J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]